(TBRG) TruBridge - Overview
Sector: Healthcare | Industry: Health Information Services | Exchange: NASDAQ (USA) | Market Cap: 389m USD | Total Return: 9.3% in 12m
Avg Turnover: 4.87M
EPS Trend: -3.8%
Qual. Beats: 0
Rev. Trend: 87.2%
Qual. Beats: 0
Warnings
P/E ratio 89.5
Altman Z'' 0.89 < 1.0 - financial distress zone
Tailwinds
Supp Ema20, Confidence
TruBridge, Inc. (TBRG) provides healthcare information technology and revenue cycle management (RCM) solutions primarily for community hospitals and clinics. The company operates through two segments: Financial Health, which focuses on billing, medical coding, and insurance claim processing, and Patient Care, which provides electronic health record (EHR) software and patient engagement tools. Formerly known as Computer Programs and Systems, Inc. (CPSI), the firm rebranded in early 2024 to unify its service offerings under a single identity.
The business model relies heavily on recurring revenue through cloud-based software-as-a-service (SaaS) and long-term support contracts. In the healthcare technology sector, community hospitals often represent a specialized niche with unique regulatory and budgetary constraints compared to large urban medical centers. RCM providers like TruBridge aim to minimize claim denials and optimize cash flow for these smaller institutions by automating complex administrative workflows.
Investors can further evaluate these operational metrics and financial trends by exploring the data available on ValueRay. Founded in 1979 and headquartered in Alabama, the company maintains a diverse portfolio that includes business intelligence, cybersecurity, and hardware replacement services tailored to the acute care market.
- Transition to high-margin SaaS revenue improves overall corporate profitability and valuation
- Revenue cycle management outsourcing demand rises as hospital labor costs escalate
- Successful integration of legacy EHR systems determines long-term client retention rates
- Regulatory changes in Medicare reimbursement impact community hospital financial health and spending
- Expansion of cloud-based security services diversifies revenue beyond traditional clinical software
| Net Income: 4.40m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 5.42 > 1.0 |
| NWC/Revenue: 13.94% < 20% (prev 10.26%; Δ 3.68% < -1%) |
| CFO/TA 0.11 > 3% & CFO 46.7m > Net Income 4.40m |
| Net Debt (137.6m) to EBITDA (42.6m): 3.23 < 3 |
| Current Ratio: 1.78 > 1.5 & < 3 |
| Outstanding Shares: last quarter (14.6m) vs 12m ago 1.36% < -2% |
| Gross Margin: 51.23% > 18% (prev 0.52%; Δ 5.07k% > 0.5%) |
| Asset Turnover: 86.87% > 50% (prev 89.36%; Δ -2.49% > 0%) |
| Interest Coverage Ratio: 1.24 > 6 (EBITDA TTM 42.6m / Interest Expense TTM 12.7m) |
| A: 0.12 (Total Current Assets 109.7m - Total Current Liabilities 61.5m) / Total Assets 407.5m |
| B: -0.03 (Retained Earnings -11.7m / Total Assets 407.5m) |
| C: 0.04 (EBIT TTM 15.8m / Avg Total Assets 398.2m) |
| D: -0.05 (Book Value of Equity -12.0m / Total Liabilities 228.9m) |
| Altman-Z'' = 0.89 = B |
| DSRI: 0.90 (Receivables 53.0m/59.0m, Revenue 345.9m/347.5m) |
| GMI: 1.02 (GM 51.23% / 52.15%) |
| AQI: 0.93 (AQ_t 0.71 / AQ_t-1 0.76) |
| SGI: 1.00 (Revenue 345.9m / 347.5m) |
| TATA: -0.10 (NI 4.40m - CFO 46.7m) / TA 407.5m) |
| Beneish M = -3.24 (Cap -4..+1) = AA |
As of June 01, 2026, the stock is trading at USD 25.96 with a total of 151,739 shares traded.
Over the past week, the price has changed by +0.23%,
over one month by +1.01%,
over three months by +36.13% and
over the past year by +9.31%.
TruBridge has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold TBRG.
- StrongBuy: 0
- Buy: 0
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 25.7 | -1.1% |
P/E Trailing = 89.5172
P/E Forward = 9.8328
P/S = 1.1253
P/B = 2.1783
P/EG = 0.3171
Revenue TTM = 345.9m USD
EBIT TTM = 15.8m USD
EBITDA TTM = 42.6m USD
Long Term Debt = 160.5m USD (from longTermDebt, last quarter)
Short Term Debt = 4.97m USD (from shortTermDebt, last quarter)
Debt = 173.1m USD (from shortLongTermDebtTotal, last quarter) + Leases 4.61m
Net Debt = 137.6m USD (calculated: Debt 173.1m - CCE 35.4m)
Enterprise Value = 527.0m USD (389.4m + Debt 173.1m - CCE 35.4m)
Interest Coverage Ratio = 1.24 (Ebit TTM 15.8m / Interest Expense TTM 12.7m)
EV/FCF = 11.81x (Enterprise Value 527.0m / FCF TTM 44.6m)
FCF Yield = 8.47% (FCF TTM 44.6m / Enterprise Value 527.0m)
FCF Margin = 12.90% (FCF TTM 44.6m / Revenue TTM 345.9m)
Net Margin = 1.27% (Net Income TTM 4.40m / Revenue TTM 345.9m)
Gross Margin = 51.23% ((Revenue TTM 345.9m - Cost of Revenue TTM 168.7m) / Revenue TTM)
Gross Margin QoQ = 47.59% (prev 54.28%)
Tobins Q-Ratio = 1.29 (Enterprise Value 527.0m / Total Assets 407.5m)
Interest Expense / Debt = 7.36% (Interest Expense 12.7m / Debt 173.1m)
Taxrate = 13.06% (76.0k / 582k)
NOPAT = 13.8m (EBIT 15.8m * (1 - 13.06%))
Current Ratio = 1.78 (Total Current Assets 109.7m / Total Current Liabilities 61.5m)
Debt / Equity = 0.97 (Debt 173.1m / totalStockholderEquity, last quarter 178.7m)
Debt / EBITDA = 3.23 (Net Debt 137.6m / EBITDA 42.6m)
Debt / FCF = 3.08 (Net Debt 137.6m / FCF TTM 44.6m)
Total Stockholder Equity = 177.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.11% (Net Income 4.40m / Total Assets 407.5m)
RoE = 2.33% (Net Income TTM 4.40m / Total Stockholder Equity 189.3m)
RoCE = 4.52% (EBIT 15.8m / Capital Employed (Equity 189.3m + L.T.Debt 160.5m))
RoIC = 3.98% (NOPAT 13.8m / Invested Capital 345.5m)
WACC = 9.25% (E(389.4m)/V(562.4m) * Re(10.52%) + D(173.1m)/V(562.4m) * Rd(7.36%) * (1-Tc(0.13)))
Discount Rate = 10.52% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 82.22 | Cagr: 1.12%
[DCF] Terminal Value 75.10% ; FCFF base≈35.4m ; Y1≈40.6m ; Y5≈59.7m
[DCF] Fair Price = 42.49 (EV 775.0m - Net Debt 137.6m = Equity 637.4m / Shares 15.0m; r=9.25% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -3.79 | EPS CAGR: -3.54% | SUE: -0.14 | # QB: 0
Revenue Correlation: 87.25 | Revenue CAGR: 1.45% | SUE: -0.83 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.68 | Chg30d=+26.44% | Revisions=+25% | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.79 | Chg30d=+24.16% | Revisions=+50% | Analysts=1
EPS current Year (2026-12-31): EPS=2.87 | Chg30d=+12.71% | Revisions=+56% | GrowthEPS=+7.7% | GrowthRev=+1.2%
EPS next Year (2027-12-31): EPS=2.97 | Chg30d=+1.60% | Revisions=+50% | GrowthEPS=+3.8% | GrowthRev=+5.6%
[Analyst] Revisions Ratio: +56%